ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

418
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
30 Jan 2024 15:49

[Blue Lotus Daily]:ACMR/300750 SZ/DIDI/NIO/1810 HK/TCOM/LKNCY/2269 HK

​Samsung Galaxy S24 pre-orders in South Korea reach nearly 1.2 million units; Luckin Coffee reduces registered capital by US$400mn; US Congress...

Share
28 Jan 2024 10:05

HK Short Interest Weekly: HSBC, China Mobile, Shk Ppt, Wuxi Bio, Kuaishou, Li Auto

We analyzed the latest HK SFC report for aggregate short position as of Jan 19th and highlight short interest changes in HSBC, China Mobile, Shk...

Logo
380 Views
Share
bullishJSR Corp
28 Jan 2024 07:00

Last Week in Event SPACE: T&K TOKA, Liquidated HK Stocks, JSR, Orecorp, Brilliance Auto, Hollysys

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

Logo
338 Views
Share
27 Jan 2024 22:36

Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong

​Samsung Biologics reported 11% YoY revenue growth in 4Q23, driven by Plant 4 operations and strong sales backlog. Resilient business performance...

Logo
406 Views
Share
26 Jan 2024 10:00

HK CEO & Director Dealings (26 Jan 2024): Sun Hung Kai, Wuxi Bio, Sichuan Kelun-Bio, Wisdom Sports

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.  These insights also flag those companies where...

Logo
498 Views
Share
x